Bloomberg Daybreak: Europe EditionOil Back Above $100, Tesla’s $25B Robot Bet, Drugs Kept From Europe

European Patients Left Waiting

16:41–17:05 · 24s

Kresge cites Insmed delaying a lung drug’s European launch to avoid triggering lower US prices, meaning patients in Europe lose access in the meantime.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.